Other publications

In 2024 HSRU produced a final report for the Chief Scientist Office (CSO) of the Scottish Government as a summary of impact achieved by the Unit over the 36 years of CSO core funding to HSRU. A copy of the report can be found here.

Boyers, D, Imamura, M, Scott, N, Kumar, S, Tsehaye, M, Cruickshank, M, Manson, P, Ormerod, T, Brazzelli, M. Secukinumab for moderate-to-severe hidradenitis suppurativa [ID4039]. Evidence Review Group report in support of NICE STA programme. University of Aberdeen: Health Services Research Unit; 2023

Boyers, D, Scott, N, Cruickshank, M, Azharuddin, M, Hernandez, R, Ayansina, D, Manson, P, Virgilli, G, Azuara-Blanco, A, and Brazzelli, M. Netarsudil-latanoprost for previously treated open-angle glaucoma or ocular hypertension [ID1363] Evidence Review Group report in support of NICE STA programme. University of Aberdeen: Health Services Research Unit; 2023

Imamura, M, Getaneh, A, Cooper, D, Cruickshank, M, Manson, P, Shaukat, AA, Brazzelli, M, Scotland, G. Ivosidenib for treating advanced cholangiocarcinoma with an IDH1 mutation after at least 1 therapy [ID6164]. Evidence Review Group report in support of NICE STA programme. University of Aberdeen: Health Services Research Unit; 2023

Boyers, D, Cruickshank, M, Scott, N, Jacobsen, E, Kumar, S, Imamura, M, Manson, P, Preston, G,Brazzelli, M. Axicabtagene for diffuse large B-cell lymphoma  [ID1684]. Evidence Review Group report in support of NICE STA programme. University of Aberdeen: Health Services Research Unit; 2022

Carter, S,Entwistle, V. Feminist Bioethics and Empirical Research In: The Routledge Handbook of Feminist Bioethics. London: Routledge; 2022.

Cruickshank, M, Cooper, D, Crozier, A, Robertson, C, Aucott, L, Manson, P, Ormerod, A, Scotland, G,Brazzelli, M. Deucravacitinib for treating moderate to severe plaque psoriasis [ID3859]. Evidence Review Group report in support of NICE STA programme. University of Aberdeen: Health Services Research Unit; 2022

Rogers, W, JL, S, Carter, S, Entwistle, V,Mills, C. The Routledge Handbook of Feminist Bioethics. London: Routledge; 2022

Scotland, G, Cruickshank, M, Ayansina, D, Imamura, M, Kumar, S, Manson, P, Booth, C, Preston, G,Brazzelli, M. Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID3860]. Evidence Review Group report in support of NICE STA programme. University of Aberdeen: Health Services Research Unit; 2022

Vadiveloo, T, Scotland, G, Booth, C, Robertson, C, Cruickshank, M, Aucott, L, Kennedy, C, Manson, P, Preston, G,Brazzelli, M. Axicabtagene ciloleucel for non-Hodgkin lymphoma [ID1685]. Evidence Review Group report in support of NICE STA programme. University of Aberdeen: Health Services Research Unit; 2022

Vadiveloo, T, Scotland, G, Booth, C, Robertson, C, Cruickshank, M, Aucott, L, Kennedy, C, Manson, P, Preston, G,Brazzelli, M. Axicabtagene ciloleucel for treating relapsed or refractory low-grade non-Hodgkin lymphoma [ID1685]. Evidence Review Group report in support of NICE STA programme. University of Aberdeen: Health Services Research Unit; 2022

Collaboration for Change. Collaboration for Change: promoting vaccine uptake. Manchester: We are Couch Ltd; 2021

Robertson, C, Booth, C, Ayansina, D, Hernandez, R, Manson, P, Herriot, R, Brazzelli, M,Scotland, G. Berotralstat for preventing acute attacks of hereditary angioedema [ID1624]. Evidence Review Group in support of NICE STA programme. University of Aberdeen: Health Services Research Unit; 2021

Cruickshank, M, Boyers, D, Scott, N, Manson, P, Lumsden, C, Scotland, G,Brazzelli, M. Palforzia for treating peanut allergy [ID1282]. Evidence Review Group in support of NICE STA programme. University of Aberdeen: Health Services Research Unit; 2021

Gillies, K, Kearney, A, Keenan, C, Treweek, S, Hudson, J, Brueton, VC, Conway, T, Hunter, A, Murphy, L, Carr, PJ, Rait, G, Manson, P,Aceves-Martins, M. Strategies to improve retention in randomised trials. Cochrane Database Syst Rev 2021;3:Mr000032.

Kennedy, C, Robertson, C, Cruickshank, M, Ayansina, D, Manson, P, Moroni, F, Brazzelli, M,Scotland, G. Teduglutide for treating short bowel syndrome [ID3937]. Evidence Review Group in support of NICE STA programme. University of Aberdeen: Health Services Research Unit; 2021

Cruickshank, M, Kennedy, C, Aucott, L, Booth, C, Imamura, M, Vadiveloo, T, Manson, P, Preston, G, Scotland, G,Brazzelli, M. Venetoclax with a hypomethylating agent or low dose cytarabine for untreated acute myeloid leukaemia unsuitable for intensive chemotherapy [ID1564]. Evidence Review Group in support of NICE STA programme. University of Aberdeen: Health Services Research Unit; 2021

Immamura, M, Kennedy, C, Aucott, L, Boyers, D, Cruickshank, M, Cooper, D, Manson, P, Ormerod, A,Brazzelli, M. Secukinumab for treating plaque psoriasis in children and young people [ID1669]. Evidence Review Group in support of NICE STA programme. University of Aberdeen: Health Services Research Unit; 2021

Lone, N, Stewart, N, McPeake, J, Puxty, K, Kaye, C, Hall, R, Haddow, C, Paton, M, Donaldson, L, Wood, R,McAllister, D. Scottish Intensive Care Society Audit Group report on COVID-19: as at 31 January 2021. Edinburgh: 2021